Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 7/20 | 0.66 |
| ▸ | CYSLTR2 | Q9NS75 | 4/20 | 0.66 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.60 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10547475 | 0.93 | CYSLTR1 (0.76) | CYSLTR1CYSLTR2PDE10AGPBAR1ALOX5 | |
| SCHEMBL13772771 | 0.90 | CYSLTR1 (0.77) | CYSLTR1CYSLTR2PDE10AGPBAR1ALOX5 | |
| SCHEMBL13772898 | 0.89 | CYSLTR1 (0.69) | CYSLTR1CYSLTR2PDE10AGPBAR1ALOX5 | |
| SCHEMBL4146604 | 0.86 | CYSLTR1 (0.66) | CYSLTR1CYSLTR2PDE10AGPBAR1ALOX5 | |
| SCHEMBL3271496 | 0.86 | CYSLTR1 (0.66) | CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| SCHEMBL8732702 | 0.82 | PDE10A (0.66) | CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| SCHEMBL10547803 | 0.82 | CYSLTR1 (0.69) | CYSLTR1CYSLTR2PDE10AGPBAR1ALOX5 | |
| SCHEMBL10607508 | 0.81 | CYSLTR1 (0.71) | CYSLTR1CYSLTR2PDE10AGPBAR1ALOX5 | |
| SCHEMBL4151512 | 0.81 | PDE10A (0.63) | CYSLTR1CYSLTR2PDE10AGPBAR1 | |
| SCHEMBL10547998 | 0.80 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2PDE10AGPBAR1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176829-A1 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PFIZER INC | 2009-07-09 | — | — | US | disclosed |
| US-20090176829-A1 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PFIZER INC | 2009-07-09 | — | — | US | disclosed |
| WO-2007129183-A2 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176829-A1 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PDE12, PDE7A, PDE9A | CYSLTR1 3635/4885CYSLTR2 3802/4885PDE10A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.